Skip to content

Press Releases

Swedish

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Administrative backlog at public authority causes short-term delay in Tourette study

(Stockholm, 16 September, 2021.) An administrative backlog due to Covid-19 at The Capital Region of Denmark (Region Hovedstaden) is causing a delay of approx. 3 months to the initiation of Asarina Pharma’s phase IIa study in Tourette Syndrome. The study is now expected to start in December 2021 and be completed at the end of…

Full PDF

Asarina Pharma AB (publ) Q2 Report 2021 released

Asarina Pharma CEO Peter Nordkild: “Q2 2021 was a difficult quarter for us and our shareholders. It was also a definitively transformative one. The failure of our Phase IIa study in Menstrual Migraine coincided with the approval of our CTA in Tourette syndrome by the Danish Medicines Agency, and the granting of our first US…

Full PDF

Asarina Pharma reports topline results in Phase IIa Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today releases topline results from its Phase IIa study of Sepranolone for the treatment of menstrual migraine. While a 25% reduction in menstrual migraine days was achieved across the patient population, a statistically significant difference compared to placebo was not obtained for the study’s primary and secondary endpoints.…

Full PDF

Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling

(Stockholm, 8 June 2021.) The US Patent and Trademark Office has granted a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and pathological gambling. CEO Peter Nordkild: “The powerful neurosteroid Allopregnanolone (ALLO) seems to be the missing link in a raft of stress-related disorders, from Tourette to OCD, characterized by tics and…

Full PDF

Asarina Pharma obtains convertible loan for continued research on neurological conditions including Obsessive Compulsive Disorder

(Stockholm, 31 May 2021) Asarina Pharma AB (publ) has obtained a convertible loan of 5.3 MSEK from Östersjöstiftelsen (ÖSS), one of its key shareholders, for ongoing and upcoming R&D into neurological disorders including OCD (Obsessive Compulsive Disorder).

Full PDF
Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders 2023-05-23 09:02 Regulatory
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) 2023-05-22 11:15 Regulatory
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America 2023-05-05 13:33
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
Asarina Pharma AB (publ) releases Annual Report 2022 2023-04-28 20:30 Regulatory Annual
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL) 2023-04-18 10:39 Regulatory
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome 2023-04-01 14:20 Regulatory
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
Asarina Pharma AB (publ) releases Year-End Report 2022 2023-02-27 08:30 Regulatory Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...
Last Patient Last Visit for landmark Tourette Syndrome study 2023-02-02 09:45 Regulatory
A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active...
Patient recruitment completed in landmark Tourette syndrome study 2022-10-14 09:50 Regulatory
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
Extensive new preclinical study significantly increases the Translatability of Asarina Pharma’s findings on key stress mechanism implicated in Tourette Syndrome and OCD 2022-10-06 08:30 Regulatory
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...
Next